Session: Radiotherapeutics: From Isotope Production to Targeted Radiotherapy:

Theranostic radiometals such as mercury-197m/g (^197m/gHg, t_1/2 = 23.8 h/64.1 h) continue to attract interest as the incorporation of these radionuclides in radiopharmaceuticals have profound potential to both image (diagnostic SPECT imaging via gamma-ray decay emissions) and treat diseases such as cancer (therapeutic radiation via Auger electrons) simultaneously, using the same drug construct. The literature surrounding ^197m/gHg radiopharmaceuticals is limited. Particularly, the underdevelopment of selective and stable bifunctional chelators (BFCs) for ^197m/gHg prevents its use in clinical radiopharmaceuticals. In this study, BFCs that efficiently coordinate to ^197m/gHg for incorporation into radiopharmaceuticals are identified by screening commercially available and novel sulfur-rich BFCs. This work includes novel ligand design and synthesis, followed by complex characterization and the determination of the radiochemical conversion for these ligands with ^197m/gHg.

Valery Radchenko

Appearances